Luis E. Aguirre, MD, is a medical oncologist and academic hematologist in the Leukemia and Myeloid Malignancy Program at Yale Cancer Center and Yale School of Medicine, where he serves as assistant professor of medicine. He specializes in myeloid blood cancers — including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and myeloproliferative neoplasms (MPNs) — and cares for both newly diagnosed and relapsed patients. He does so with an emphasis on risk-adapted, biology-informed treatment selection and clinical-trial access when appropriate.
“The most important thing I want patients to know is that I am deeply committed to caring for them as a unique person, not as a diagnosis or a statistic,” he says. “I am a highly data-driven and evidence-based physician, and I take that responsibility seriously. I spend a great deal of time understanding the details of a patient’s disease: its biology, genetics, clinical behavior, and trajectory, because precision matters. But I also believe that excellent care is never just about the data. Two patients with the same diagnosis may have very different priorities, goals, tolerances, and life circumstances, and those differences should shape treatment decisions in a meaningful way.”
Dr. Aguirre’s academic program emphasizes the development of scalable clinical-genomic data infrastructure to enable rigorous, reproducible retrospective investigation, and the design and execution of early-phase clinical trials. His research leverages real-world outcomes data coupled with deep genomic and therapeutic annotation to generate data-driven frameworks that improve trial design.
“What drew me to malignant hematology, especially myeloid malignancies, was the intellectual depth of the field and the opportunity to make a meaningful difference in patients’ lives through truly personalized, biology-informed care,” he says. “I have always been drawn to the intersection of clinical medicine, genomics, and quantitative reasoning.
“My long-term goal is to build a career that meaningfully bridges excellent clinical care, rigorous clinical investigation, and translational discovery in myeloid malignancies. I want to care for patients with the same level of precision and thoughtfulness that I bring to research: evidence-based, individualized, and grounded in a deep understanding of disease biology and kinetics. From a research standpoint, my goal is to develop a program that integrates clinical-genomic data infrastructure, real-world outcomes research, and early-phase clinical trials with correlative science.”
Dr. Aguirre completed residency training in internal medicine at the University of Miami Miller School of Medicine, followed by fellowship training in hematology and medical oncology at the H. Lee Moffitt Cancer Center. He subsequently pursued advanced leukemia training as the Foley Family Advanced Fellow in Leukemia at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, where he cared for highly complex patients with acute leukemias and related myeloid neoplasms while participating in investigator-initiated clinical trials and translational research initiatives.
